Barclays Starts Coverage On Allegion PLC (ALLE) with $100 Target; 4 Analysts Covering Adamis Pharmaceuticals (ADMP)

February 15, 2018 - By Marguerite Chambers

Among 12 analysts covering Allegion PLC (NYSE:ALLE), 9 have Buy rating, 0 Sell and 3 Hold. Therefore 75% are positive. Allegion PLC has $100.0 highest and $65 lowest target. $86.33’s average target is 7.95% above currents $79.97 stock price. Allegion PLC had 28 analyst reports since August 3, 2015 according to SRatingsIntel. Susquehanna maintained the stock with “Hold” rating in Friday, January 12 report. The firm has “Outperform” rating by Imperial Capital given on Tuesday, November 1. The stock of Allegion plc (NYSE:ALLE) has “Outperform” rating given on Friday, February 10 by Imperial Capital. The company was maintained on Thursday, October 26 by Robert W. Baird. The stock of Allegion plc (NYSE:ALLE) has “Buy” rating given on Friday, February 12 by Credit Agricole. The rating was maintained by Imperial Capital with “Outperform” on Friday, May 5. The rating was maintained by Credit Suisse on Monday, May 1 with “Buy”. The stock has “Outperform” rating by Imperial Capital on Thursday, January 14. Imperial Capital downgraded Allegion plc (NYSE:ALLE) on Tuesday, August 2 to “In-Line” rating. The firm earned “Buy” rating on Monday, October 17 by CLSA.

Among 4 analysts covering Adamis Pharma (NASDAQ:ADMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharma had 9 analyst reports since December 1, 2015 according to SRatingsIntel. As per Tuesday, December 1, the company rating was initiated by Maxim Group. Maxim Group maintained Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) rating on Monday, August 21. Maxim Group has “Buy” rating and $13.0 target. Raymond James maintained the stock with “Buy” rating in Monday, December 4 report. The rating was initiated by Raymond James on Tuesday, September 12 with “Buy”. Maxim Group maintained the shares of ADMP in report on Monday, June 12 with “Buy” rating. The stock has “Buy” rating by Maxim Group on Thursday, July 21. See Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) latest ratings:

04/12/2017 Broker: Raymond James Rating: Buy New Target: $7.0 Maintain
15/11/2017 Broker: FBR Capital Rating: Buy New Target: $9.5
04/10/2017 Broker: B. Riley & Co Rating: Buy New Target: $9.5
12/09/2017 Broker: Raymond James Rating: Buy New Target: $7.0 Initiate
21/08/2017 Broker: Maxim Group Rating: Buy New Target: $13.0 Maintain

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company has market cap of $115.19 million. The companyÂ’s specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease. It currently has negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.

The stock decreased 4.17% or $0.15 during the last trading session, reaching $3.45. About 800,557 shares traded or 15.98% up from the average. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has declined 52.09% since February 15, 2017 and is downtrending. It has underperformed by 68.79% the S&P500.

Allegion Public Limited Company manufactures and sells mechanical and electronic security products and solutions worldwide. The company has market cap of $7.60 billion. It offers locks, locksets, portable locks, and key systems; door closers and controls/exit devices; electronic security products and access control systems; time, attendance, and workforce productivity systems; doors and door frames; and other accessories. It has a 22.73 P/E ratio. It also makes door and window products, including sealing systems, such as sound control, fire and smoke protection, threshold applications, lights, door louvers, intumescent products, photo-luminescent, and flood barrier for doors for use in commercial spaces and products, as well as creates and makes sliding and folding door hardware for commercial and residential spaces.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: